Erratum: Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP (Diabetes Care (2017) 40 (1733-1738) DOI: 10.2337/dc17-1366);Intensive versus standard blood pressure control in SPRINTE-ligible participants of ACCORD-BP

Diabetes Care

Volumn 40, Issue 12, 2017, Pages 1733-1738

  Buckley, Leo F ^a   Dixon, Dave L ^a   Wohlford, George F ^a   Wijesinghe, Dayanjan S ^a   Baker, William L ^b   Van Tassell, Benjamin W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FRAMINGHAM RISK SCORE; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTENSIVE BLOOD PRESSURE CONTROL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM; STANDARD BLOOD PRESSURE CONTROL; AGED; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; HYPERTENSION; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 85036663362     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-er09     Document Type: Erratum

References (20)

1. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-113
2. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, and Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419
3. Preis SR, Pencina MJ, Hwang S-J, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009;120:212-220
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascularmortality: ameta-analysis of individual data for onemillion adults in 61 prospective studies. Lancet 2002;360:1903-1913
5. Oparil S, Lewis CE. Should patientswith cardiovascular risk factors receive intensive treatment of hypertension to, 120/80 mmHg target? A protagonist view from the SPRINT Trial (Systolic Blood Pressure Intervention Trial). Circulation 2016;134:1308-1310
6. Lonn EM, Yusuf S. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to, 120/80 mmHg target? An antagonist view from the HOPE-3 Trial (Heart Outcomes Evaluation-3). Circulation 2016;134: 1311-1313
7. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585
8. Wright JT, Williamson JD, Whelton PK, et al.; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116.
9. Bress AP, Tanner RM, Hess R, et al. Prevalence of eligibility criteria for the systolic blood pressure intervention trial in US adults among excluded groups: age,50 years, diabetes mellitus, or a history of stroke. J Am Heart Assoc 2016;5:e003547
10. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol 2016;67:463-472
11. Cushman WC, Grimm RH, Cutler JA, et al.; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol 2007;99:S44i-S55i
12. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
13. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532-546
14. American Diabetes Association. Standards of medical care in diabetesd2017. Diabetes Care 2017;40(Suppl. 1):S1-S135
15. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-443
16. Bress A, Beddhu S, King J, et al. Intensive blood pressure control reduces cardiovascular events in patients with prediabetes. Diabetes 2017;66(Suppl. 1):A212
17. Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl JMed 2016;374:2009-2020
18. Navar AM, Pencina MJ, Peterson ED. Assessing cardiovascular risk to guide hypertension diagnosis and treatment. JAMA Cardiol 2016;1: 864-871
19. Varshney A, Steg PG, Elbez Y, Sorbets E, Eagle KA, Bhatt DL. Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: a REACH registry analysis. Int J Cardiol 2017;243:95-97
20. Margolis KL, O'Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014; 37:1721-1728